Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHDX Genomic Health	$63.44	$64.79	$50.77 ▼ $90.18	$2.38B	0.9	1.05 million shs	N/A
HALO Halozyme Therapeutics	$56.45 -2.4%	$54.48	$42.01 ▼ $70.51	$6.96B	1.15	1.75 million shs	1.11 million shs
IONS Ionis Pharmaceuticals	$41.76 -1.0%	$37.11	$23.95 ▼ $52.34	$6.65B	0.23	1.62 million shs	1.27 million shs
RGEN Repligen	$116.25 -6.3%	$124.79	$102.97 ▼ $182.52	$6.53B	1.11	728,167 shs	1.03 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHDX Genomic Health	0.00%	0.00%	0.00%	0.00%	0.00%
HALO Halozyme Therapeutics	-0.34%	+0.31%	+8.85%	-1.67%	+5.59%
IONS Ionis Pharmaceuticals	-1.40%	-0.50%	+16.65%	+48.49%	-12.07%
RGEN Repligen	+3.58%	-7.43%	+2.50%	-4.58%	-6.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHDX Genomic Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	4.9604 of 5 stars	3.1	4.0	0.0	4.4	2.9	2.5	4.4
IONS Ionis Pharmaceuticals	4.4718 of 5 stars	4.4	2.0	0.0	3.0	2.1	3.3	0.6
RGEN Repligen	4.714 of 5 stars	4.3	1.0	0.0	4.5	3.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHDX Genomic Health	0.00	N/A	N/A	N/A
HALO Halozyme Therapeutics	2.17	Hold	$62.70	11.07% Upside
IONS Ionis Pharmaceuticals	2.76	Moderate Buy	$57.13	36.81% Upside
RGEN Repligen	2.69	Moderate Buy	$170.75	46.88% Upside

Current Analyst Ratings Breakdown

Latest GHDX, RGEN, HALO, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$58.00 ➝ $60.00
7/10/2025	HALO Halozyme Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$55.00
7/8/2025	RGEN Repligen	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$140.00 ➝ $130.00
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/24/2025	RGEN Repligen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$150.00
6/12/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $48.00
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/20/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/14/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $62.00
5/13/2025	HALO Halozyme Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHDX Genomic Health	$394.11M	6.05	$1.45 per share	43.76	$7.48 per share	8.48
HALO Halozyme Therapeutics	$1.08B	6.42	$4.53 per share	12.47	$2.86 per share	19.74
IONS Ionis Pharmaceuticals	$705M	9.43	N/A	N/A	$3.73 per share	11.20
RGEN Repligen	$634.44M	10.29	$3.02 per share	38.54	$35.21 per share	3.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHDX Genomic Health	$25.68M	$1.05	60.42	36.88	N/A	12.81%	19.62%	14.89%	N/A
HALO Halozyme Therapeutics	$444.09M	$3.76	15.01	9.08	0.39	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)
RGEN Repligen	-$25.51M	-$0.45	N/A	49.26	3.43	-3.93%	4.53%	3.17%	7/29/2025 (Estimated)

Latest GHDX, RGEN, HALO, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	HALO Halozyme Therapeutics	$1.22	N/A	N/A	N/A	$282.66 million	N/A
7/30/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	N/A	N/A	N/A	$270.90 million	N/A
7/29/2025	Q2 2025	RGEN Repligen	$0.40	N/A	N/A	N/A	$174.62 million	N/A
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
4/29/2025	Q1 2025	RGEN Repligen	$0.35	$0.39	+$0.04	$0.10	$163.65 million	$169.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHDX Genomic Health	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHDX Genomic Health	0.15	5.96	5.96
HALO Halozyme Therapeutics	3.13	8.39	7.30
IONS Ionis Pharmaceuticals	2.63	9.66	9.62
RGEN Repligen	0.27	6.79	5.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHDX Genomic Health	93.87%
HALO Halozyme Therapeutics	97.79%
IONS Ionis Pharmaceuticals	93.86%
RGEN Repligen	97.64%

Insider Ownership

Company	Insider Ownership
GHDX Genomic Health	31.30%
HALO Halozyme Therapeutics	2.40%
IONS Ionis Pharmaceuticals	2.60%
RGEN Repligen	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHDX Genomic Health	829	37.59 million	N/A	Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.26 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	155.02 million	Optionable
RGEN Repligen	1,778	56.18 million	55.51 million	Optionable

GHDX, RGEN, HALO, and IONS Headlines

Recent News About These Companies

Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks

2 hours ago | msn.com

3 Reasons RGEN is Risky and 1 Stock to Buy Instead

2 hours ago | msn.com

Repligen Corp (RGEN) Trading Down 4.19% on Jul 18

July 18 at 1:43 PM | gurufocus.com

Q1 Earnings Estimate for Repligen Issued By Leerink Partnrs

July 18 at 10:53 AM | marketbeat.com

Repligen to Report Second Quarter 2025 Financial Results

July 17 at 7:30 AM | globenewswire.com

Segall Bryant & Hamill LLC Grows Stake in Repligen Corporation (NASDAQ:RGEN)

July 17 at 6:51 AM | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Shares Acquired by Rice Hall James & Associates LLC

July 15 at 5:45 AM | marketbeat.com

Repligen (NASDAQ:RGEN) Trading Down 5.4% - Here's Why

July 14, 2025 | marketbeat.com

TimesSquare Capital Management LLC Has $30.03 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

July 14, 2025 | marketbeat.com

Slow Capital Inc. Has $4.18 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

July 14, 2025 | marketbeat.com

New York State Common Retirement Fund Grows Holdings in Repligen Corporation (NASDAQ:RGEN)

July 14, 2025 | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Shares Bought by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

Teacher Retirement System of Texas Increases Stake in Repligen Corporation (NASDAQ:RGEN)

July 11, 2025 | marketbeat.com

Banque Pictet & Cie SA Has $3.12 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)

July 10, 2025 | marketbeat.com

Principal Financial Group Inc. Increases Position in Repligen Corporation (NASDAQ:RGEN)

July 9, 2025 | marketbeat.com

Repligen And 2 Other Stocks That May Be Trading Below Estimated Value

July 8, 2025 | finance.yahoo.com

Evercore ISI Cuts Repligen (NASDAQ:RGEN) Price Target to $130.00

July 8, 2025 | marketbeat.com

New York State Teachers Retirement System Has $6.49 Million Holdings in Repligen Corporation (NASDAQ:RGEN)

July 6, 2025 | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plc

July 5, 2025 | marketbeat.com

1 Healthcare Stock to Target This Week and 2 to Be Wary Of

July 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Blockchain Stocks to Profit in a Decentralized World
By Chris Markoch | June 24, 2025
View 3 Blockchain Stocks to Profit in a Decentralized World

GHDX, RGEN, HALO, and IONS Company Descriptions

Genomic Health NASDAQ:GHDX

Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.

Halozyme Therapeutics NASDAQ:HALO

$56.45 -1.36 (-2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$56.44 -0.01 (-0.01%)

As of 06:19 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Ionis Pharmaceuticals NASDAQ:IONS

$41.76 -0.41 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$41.76 +0.01 (+0.01%)

As of 04:10 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Repligen NASDAQ:RGEN

$116.25 -7.79 (-6.28%)

Closing price 04:00 PM Eastern

Extended Trading

$116.61 +0.36 (+0.31%)

As of 06:01 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time